



ANNUAL GENERAL MEETING

FRIDAY 28th MAY 2021

FOR THE YEAR ENDED 31 DECEMBER 2020

herbs of gold™





AGENDA

1. CHAIRMAN'S WELCOME ADDRESS
2. MANAGING DIRECTOR'S REVIEW
3. ORDINARY RESOLUTIONS
4. QUESTION & ANSWER

CHAIRMAN'S WELCOME ADDRESS

HENRY TOWNSING CHAIRMAN



Mr Townsing brings over 30 years' experience in corporate finance and private equity. He was a Director of the Company, from 1985 to 1992, 2004 to 2009 and was reappointed a Director on 22nd December 2011.

Mr Townsing was appointed as the Chairman of the Company effective 28th May 2021 and is also the chairman of the Company's Board Nomination and Remuneration Committees.

MANAGING DIRECTOR'S REVIEW

ANDREW O'KEEFE MANAGING DIRECTOR



Mr O'Keefe was appointed Managing Director on 1st January 2017.

Mr O'Keefe has over 20 years' experience within the Australian pharmaceutical and healthcare industry. During his career Mr O'Keefe has held senior leadership positions in publicly listed companies and was the CEO of Australia's largest health food distributor and retailer. Andrew O'Keefe was appointed to the position of Chief Executive Officer – Herbs of Gold Australia in October 2014.

LEADERSHIP TEAM



ANDREW O'KEEFE
MANAGING DIRECTOR



CHIN L KHOO
CHIEF FINANCIAL OFFICER



SHAUN RUTHERFORD
GLOBAL SALES DIRECTOR



MELISSA PEREIRA
HEAD OF MARKETING



KS BEH
GENERAL MANAGER, MALAYSIA
& SINGAPORE



RENEE TI
SENIOR CORPORATE MANAGER



SUAT LING KOAY
GENERAL MANAGER,
NEW PRODUCT DEVELOPMENT
& REGULATORY AFFAIRS,
SOUTH EAST ASIA



JUNE LAU
GENERAL MANAGER,
OPERATIONS & BUSINESS
SUPPORT, AUSTRALIA



SANDRA VELASQUEZ
REGULATORY AFFAIRS MANAGER,
AUSTRALIA



ALEXANDRA WARD
TECHNICAL & NEW PRODUCT
DEVELOPMENT MANAGER,
AUSTRALIA

OVERVIEW


Vita Life Sciences is a multinational healthcare company involved in the formulating and distribution of high quality vitamins and supplements across the Asia Pacific region

VALUES

Vita Life Sciences has a companywide commitment to:

- Focus its efforts on the health and well-being of customers
- Conduct activities in a socially responsible manner
- Create a conducive working environment for its employees
- Provide competitive returns on shareholders' investment

HISTORY



PRODUCT PORTFOLIO

herbs of gold™



VitaHealth™



Nervous System

Children's Health

Nutritional Oils

Immunity

Hair, Skin & Nails

Liver & Digestion

Nutritionals

Weight Management

Cardiovascular Health

Pain & Inflammation

Pregnancy & Breastfeeding

Men's Health

Women's Health


Antioxidants

Bones & Joints

BRANDING


herbs of gold™

VitaHealth™



LOOK-BACK GROWTH DELIVERED

3 years ago the business implemented a strategic plan to stimulate sales after consistent periods of stagnant growth



KEY FINANCIAL INSIGHTS

Pre-Tax Profit




Higher marketing investment was required in 2018/2019 to support our growth strategy, which impacted short term pre-tax profits



2020 required a deliberate strategy to reduce normalised marketing investment of approximately \$2m

Sales



Higher sales combined with lower operating costs generated a stronger pre-tax profit




Record group sales of \$46.5m in 2020

2020 HIGHLIGHTS

- ✓ Record Group sales of \$46.5m, an increase of 9.5% on PCP
- ✓ New distribution channels delivered record sales performance across key markets in Australia and Malaysia
- ✓ Immunity products supporting consumers health and wellbeing during COVID -19 stimulated category performance
- ✓ New strategic partnerships in China is generating solid organic growth through the cross border E -Commerce Channel (CBEC)
- ✓ Comprehensive brand and product offering across all major E-Commerce platforms within South East Asia continues to broaden consumer reach
- ✓ 12 new products launched across the Herbs of Gold and VitaHealth brands, stimulating innovation across the category
- ✓ Financial strength – a balance sheet with equity of \$24.4m and a net cash balance of \$13.0m (after bank borrowings)
- ✓ Record fully franked full year dividend payment of 4.25 cents per share


KEY REVENUE

2020 Revenue by Geography



TOTAL REVENUE: \$46.5M

2019 Revenue by Geography



TOTAL REVENUE: \$42.4M

FUTURE INVESTMENT PILLARS

Brand building

Group investment strategy to drive consumer & retailer engagement



Education and Innovation

Group investment to deliver a high quality education program that supports existing & new products



Talent wellbeing

Group investment on talent acquisition to support growth expectations across the region



Operational leverage

Group investment on ERP integration across the business to provide supply chain & customer interface efficiencies



The Group plans to invest an additional **\$5-6m** across the key investment pillars over the next 3 years

OUTLOOK & GUIDANCE

- The impact of Covid 19 remains a fluid situation, which may disrupt traditional selling channels
- Management remains confident to deliver first half growth
- First Half FY 2021 sales of around, \$23.5m – \$24.5m (H1 2020: \$22.0m)
- First Half FY 2021 EBIT of around, \$4.0m – \$4.5m (H1 2020: \$4.2m)
- Higher sales contributions from core markets, including export channel underpins this result



ORDINARY RESOLUTIONS

ORDINARY RESOLUTIONS

- 1. REMUNERATION REPORT**
- 2. RE-ELECTION OF DIRECTOR - MR GREGORY RALPH**
- 3. INCREASE IN NON-EXECUTIVE DIRECTOR AGGREGATE REMUNERATION**
- 4. SHARE BUY BACK**
- 5. LONG TERM INCENTIVE PLAN SHARES-MANAGING DIRECTOR**

PROXY-RESOLUTION 1

RESOLUTIONS		IN FAVOUR	AGAINST	PROXY'S DISCRETION	EXCLUDED
1)	Adoption of the Remuneration Report	25,959,006	52,478	4,181	9,846,013

PROXY-RESOLUTION 2

RESOLUTIONS		IN FAVOUR	AGAINST	PROXY'S DISCRETION	EXCLUDED
2)	Re-election of Director (Mr Gregory Ralph)	35,837,497	20,000	4,181	0

PROXY-RESOLUTION 3

RESOLUTIONS		IN FAVOUR	AGAINST	PROXY'S DISCRETION	EXCLUDED
3)	Increase in Aggregate Remuneration of Non-Executive Directors	24,430,546	33,521	4,181	11,393,430

PROXY-RESOLUTION 4

RESOLUTIONS		IN FAVOUR	AGAINST	PROXY'S DISCRETION	EXCLUDED
4)	Share buy-back	35,857,497	0	4,181	0

PROXY-RESOLUTION 5

RESOLUTIONS		IN FAVOUR	AGAINST	PROXY'S DISCRETION	EXCLUDED
5)	Long Term Investment Plan Shares - Managing Director	24,402,036	67,021	4,181	11,388,440

PROXY

RESOLUTIONS		IN FAVOUR	AGAINST	PROXY'S DISCRETION	EXCLUDED
1)	Adoption of the Remuneration Report	25,959,006	52,478	4,181	9,846,013
2)	Re-election of Director (Mr Gregory Ralph)	35,837,497	20,000	4,181	0
3)	Increase in Aggregate Remuneration of Non-Executive Directors	24,430,546	33,521	4,181	11,393,430
4)	Share buy-back	35,857,497	0	4,181	0
5)	Long Term Investment Plan Shares - Managing Director	24,402,036	67,021	4,181	11,388,440



QUESTION & ANSWER

THANK YOU



DISCLAIMER: This document has been prepared by Vita Life Sciences Limited (Vita Life Sciences) and comprises written material/slides for a presentation concerning Vita Life Sciences.

The presentation is for information purposes only and does not constitute nor form part of any offer or invitation to acquire, sell or otherwise dispose of, or issue, or any solicitation of any offer to sell or otherwise dispose of, purchase, or subscribe for, any securities, nor does it constitute investment advice, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision.

Certain statements in this presentation are forward looking statements that have not been independently verified. These forward looking statements speak only as at the date of this presentation. These statements are based on certain assumptions, expectations, estimates, projections and beliefs and, by their nature, are subject to a number of known and unknown risks and uncertainties that could cause the actual results, performances and achievements to differ materially from any expected future results, performance or achievements expressed or implied by such statements.

No representation, warranty or assurance (express

or implied) is given or made by Vita Life Sciences that the forward looking statements contained in this presentation are accurate, complete, reliable or adequate or that they will be achieved or prove to be correct. Except for any statutory liability which cannot be excluded, Vita Life Sciences and its respective directors, officers, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the forward looking statements and exclude all liability whatsoever (including negligence) for any direct or indirect loss of damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom.

Subject to any continuing obligation under applicable law or any relevant listing rules of the ASX, Vita Life Sciences disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in these materials to reflect any change in expectations in relation to any forward looking statements or any change of events, conditions, or circumstances on which any statement is based. Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of Vita Life Sciences since the date of this presentation.